The latest price target for Ironwood Pharmaceuticals (NASDAQ:IRWD) was reported by JMP Securities on January 30, 2025. The analyst firm set a price target for $14.00 expecting IRWD to rise to within 12 months (a possible 669.06% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ:IRWD) was provided by JMP Securities, and Ironwood Pharmaceuticals maintained their market outperform rating.

There is no last upgrade for Ironwood Pharmaceuticals

There is no last downgrade for Ironwood Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on January 30, 2025 so you should expect the next rating to be made available sometime around January 30, 2026.

While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a maintained with a price target of $23.00 to $14.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $1.82, which is out of the analyst’s predicted range.